Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.32 |
| ▸ | RELA | Q04206 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863463 | 0.86 | F10 (0.36) | IRAK4MRGPRX4F10F2TP53 | |
| SCHEMBL31393761 | 0.86 | F10 (0.36) | IRAK4MRGPRX4F10F2TP53 | |
| SCHEMBL7892810 | 0.85 | IRAK4 (0.35) | IRAK4MRGPRX4F10F2TP53 | |
| SCHEMBL7900095 | 0.84 | SMN1; SMN2 (0.38) | IRAK4MRGPRX4F10SMN1; SMN2RAB9A | |
| SCHEMBL10204500 | 0.83 | F10 (0.40) | MRGPRX4F10F2SMN1; SMN2RAB9A | |
| SCHEMBL20298753 | 0.82 | F10 (0.40) | MRGPRX4F10TP53PKMNFKB1 | |
| SCHEMBL5341608 | 0.79 | MRGPRX4 (0.52) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL9186654 | 0.78 | IRAK4 (0.33) | IRAK4MRGPRX4F10TP53PKM | |
| SCHEMBL8320447 | 0.77 | LOXL2 (0.56) | MRGPRX4SMN1; SMN2RAB9ATSHR | |
| SCHEMBL12095859 | 0.77 | SMN1; SMN2 (0.41) | MRGPRX4TP53PKMNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20050020566-A1 | Novel carbapenem compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1443047-A1 | NOVEL CARBAPENEM COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020566-A1 | Novel carbapenem compounds | HPN, PRSS1, BPGM | IRAK4 3519/4885MRGPRX4 4170/4885F10 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.